Accueil   Diary - News   All news ERYTECH announces enrollment of first patient in Phase I/II study of ERY-ASP in Acute Lymphoblastic Leukemina in the United States

ERYTECH announces enrollment of first patient in Phase I/II study of ERY-ASP in Acute Lymphoblastic Leukemina in the United States

ERYTECH Pharma, the French biopharmaceutical compny that develops innovative "tumor starvation" treatments for acute leukemia and other oncology indications with unmet medical needs, annonces the enrollments of the first patient in its Phase I/II study with ERY-ASP in Acute Lymphoblastic Leukemina (ALL), in Phase IIb in Acute Myeloid Leukemia (AML) and in Phase II in pancreas cancer.

 

Read the press release